CBD-to-THC Conversion Claims Need to Distinguish Simulated Gastric Chemistry From Human Evidence

A 2017 analysis argued that CBD conversion observed in simulated gastric fluid could not be directly extrapolated to people taking oral CBD. Demonstrating a chemical reaction under artificial conditions is a different question from demonstrating it inside the human body.

The experimental environment was central

The authors examined how the simulated conditions differed from physiological conditions. Their argument concerned the relevance of a particular in-vitro model, not a claim that CBD can never undergo chemical conversion under any circumstances.

Human observations supplied another comparison

The source discussed the lack of observed conversion to THC and its metabolites in the human evidence it reviewed, including high-dose oral exposure. It also compared the reported clinical effects with a THC-like adverse-effect profile. Those observations support a bounded historical argument rather than an absolute proof covering every future preparation.

A product-positive test raises a separate question

Whether a product already contains THC is distinct from whether CBD is converted after ingestion. Rejecting a conversion explanation does not establish that every product marketed as CBD is THC-free. Neither hypothesis should be assigned to an individual result without relevant evidence.

Interpreting the evidence

A sound conversion claim identifies the reaction conditions, measured compounds and human evidence. This analysis does not provide a guarantee against a positive test from all CBD products, nor does a simulated-fluid reaction establish human intoxication after CBD use.

Related reading: interpreting cannabis tolerance claims.

Research reference

Gerhard Nahler; Franjo Grotenhermen; Antonio Waldo Zuardi; José A.S. Crippa (2017). A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. Cannabis and Cannabinoid Research. doi:10.1089/can.2017.0009.

This discussion draws on the abstract and introductory material in the supplied research synthesis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Isolated-Heart Study Linked Angiotensin Responses to Endocannabinoid Signaling Without Testing Marijuana

A 2021 rat-heart experiment found evidence that endogenous cannabinoid signaling modulated angiotensin II responses. The intervention and model did not establish the cardiovascular effects of using marijuana or taking THC. The preparation isolated a mechanistic question Researchers used perfused rat hearts and confirmed cardiac CB1 receptor expression. Angiotensin infusions changed…

Spread the love

Read Article: An Isolated-Heart Study Linked Angiotensin Responses to Endocannabinoid Signaling Without Testing Marijuana

An Isolated Intestinal Cannabinoid Study Found Two-Way Cross-Tolerance but Unequal Antagonist Withdrawal Responses

A 1999 isolated guinea-pig intestinal-tissue experiment found bidirectional cross-tolerance between morphine and WIN 55,212-2. Yet antagonist-triggered contraction did not appear symmetrically, limiting a simple claim that the two dependence states were identical. The model measured tissue responses Myenteric-plexus longitudinal-muscle preparations were incubated with the compounds and tested through electrically evoked…

Spread the love

Read Article: An Isolated Intestinal Cannabinoid Study Found Two-Way Cross-Tolerance but Unequal Antagonist Withdrawal Responses

A Mouse THC Withdrawal Model Used Receptor Blockade Rather Than Ordinary Abstinence

A 1998 mouse study used a CB1 antagonist to precipitate withdrawal after repeated THC. Its behavioral findings support an experimental dependence model, while remaining different from the natural course of human cannabis withdrawal. The trigger was an administered antagonist After repeated THC, antagonist challenge promptly increased paw tremors and head…

Spread the love

Read Article: A Mouse THC Withdrawal Model Used Receptor Blockade Rather Than Ordinary Abstinence

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us